Business
The Beauty Health Company Announces Convertible Debt Refinancing
Refinancing extends maturity of existing debt and strengthens Company’s financial position to advance growth strategyLONG BEACH, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced that it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Exchanging Holders”) of the Company’s outstanding 1.25% convertible senior notes due 2026 (the “Existing Notes”). “Our
About this update from Skinhealth Systems Inc.
[{"type":"image","alt":"The Beauty Health Company","displaySize":"","headline":null,"caption":"The Beauty Health Company","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/6182895e1e81ff6be379eee85f793155"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iytDc0r0Zjq4BlufkxkLIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6182895e1e81ff6be379eee85f793155","width":300,"height":32}},"lazy":false},{"type":"text","content":"Refinancing extends maturity of existing debt and strengthens Company’s financial position to advance growth strategy","length":117,"tagName":"p"},{"type":"text","content":"LONG BEACH, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced that it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Exchanging Holders”) of the Company’s outstanding 1.25% convertible senior notes due 2026 (the “Existing Notes”).","length":377,"tagName":"p"},{"type":"text","content":"“Our refinancing marks a critical step in strengthening our financial position and extending a portion of our debt maturity, giving us greater flexibility to invest in long-term, profitable growth,” said BeautyHealth Chief Executive Officer Marla Beck. “With a robust pipeline of innovation and bold brand initiatives, we’re focused on enhancing commercial execution, accelerating science-backed product development, and deepening provider engagement.”","length":452,"tagName":"p"},{"type":"text","content":"Under the terms of the Exchange Agreements, the Company will exchange approximately $413.2 million of aggregate principal amount of the Existing Notes for $250.0 million of new 7.95% convertible senior secured notes due 2028 (the “New Notes”), along with an aggregate of approximately $143.4 million in cash, including accrued and unpaid interest (the “Exchange”). The New Notes will be senior, secured obligations of the Company, will be guaranteed by certain of the Company’s subsidiaries (including the Company’s material domestic, wholly owned subsidiaries), and will bear interest at a rate of 7.95% per annum. Subject to certain restrictions, noteholders may convert the New Notes at any time until two schedul...